CoChat

Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment

Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G., Annibale, B. · 2002 · Alimentary Pharmacology & Therapeutics
Cited by 37

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: It has been reported that 50% of patients with atrophic body gastritis have positive Helicobacter pylori antibody titres only. In atrophic body gastritis, a decrease in H. pylori antibodies after eradication treatment has been reported, suggesting that serology may indicate an active H. pylori infection. Aim: To investigate the time course of H. pylori antibodies and gastric inflammation after eradication treatment in patients with atrophic body gastritis, and to determine whether serology alone can be considered as a valid tool to assess the efficacy of eradication treatment in patients with atrophic body gastritis. Methods: Twenty‐seven patients with atrophic body gastritis (12 serologically H. pylori‐positive only, ABG‐S+; 15 H. pylori‐positive at histology and serology, ABG‐H+) were included in the treatment group, and 17 patients (all ABG‐S+) in the no treatment group. All patients had gastroscopy plus biopsies evaluated according to the updated Sydney system and H. pylori immunoglobulin G determination: in the treatment group, at baseline and 6 and 24 months after eradication (bismuth‐based triple regimens); in the no treatment group, at baseline and after 3 years. Results: In the treatment group, in ABG‐S+ patients, H. pylori antibodies decreased significantly 6 months after treatment [37.5 U/mL (16–100 U/mL) vs. 15 U/mL (0–100 U/mL), P < 0.01], but 2 years after treatment no further decrease occurred. In addition, in ABG‐H+ patients, a significant decrease in H. pylori antibodies occurred 6 months after treatment [45 U/mL (12.5–100 U/mL) vs. 31 U/mL (0–65 U/mL), P < 0.01], but a further decrease was also observed 2 years after treatment [20 U/mL (0–56 U/mL), P < 0.01]. In ABG‐S+ patients, no correlation was observed between the H. pylori antibodies and gastric inflammation score, whereas, in the ABG‐H+ group, this correlation was extremely significant (r=0.5991, P < 0.0001). In the no treatment group, at follow‐up, a significant decrease in H. pylori antibodies was observed [26 U/mL (15–100 U/mL) vs. 22 U/mL (0–53 U/mL), P < 0.05], but the gastric body inflammation remained unchanged. Conclusions: This study shows that, in ABG‐S+ patients after eradication treatment, serology does not keep in step with gastric inflammation. This suggests that, in patients with atrophic body gastritis, serology alone may not be valid for the assessment of the efficacy of eradication treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2002.01213.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 37

Metadata

Authors
Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G., & Annibale, B.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-03
Volume
16
Issue
3
Pages
507-514
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2047381680
Cited by
37
References
2
FWCI
2.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. https://app.cochat.ai/papers/10.1046/j.1365-2036.2002.01213.x
The paper
Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G., & Annibale, B. (2002). Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2002.01213.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.